{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:58:37Z","timestamp":1780927117486,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["IP-11-2013-1615"],"award-info":[{"award-number":["IP-11-2013-1615"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["IP-11-2013-1615"],"award-info":[{"award-number":["IP-11-2013-1615"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["IP-11-2013-1615"],"award-info":[{"award-number":["IP-11-2013-1615"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["IP-11-2013-1615"],"award-info":[{"award-number":["IP-11-2013-1615"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["IP-11-2013-1615"],"award-info":[{"award-number":["IP-11-2013-1615"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["IP-11-2013-1615"],"award-info":[{"award-number":["IP-11-2013-1615"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["IP-11-2013-1615"],"award-info":[{"award-number":["IP-11-2013-1615"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["IP-11-2013-1615"],"award-info":[{"award-number":["IP-11-2013-1615"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["IP-11-2013-1615"],"award-info":[{"award-number":["IP-11-2013-1615"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["IP-11-2013-1615"],"award-info":[{"award-number":["IP-11-2013-1615"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Unlike other tumours, <jats:italic>TP53<\/jats:italic> is rarely mutated in melanoma; however, it fails to function as a tumour suppressor. We assume that its functions might be altered through interactions with several families of proteins, including p53\/p73, NME and GLI. To elucidate the potential interplay among these families we analysed the expression profiles of aforementioned genes and proteins in a panel of melanoma cell lines, metastatic melanoma specimens and healthy corresponding tissue. Using qPCR a higher level of <jats:italic>NME1<\/jats:italic> gene expression and lower levels of \u039440p53\u03b2, \u0394Np73, <jats:italic>GLI1<\/jats:italic>, <jats:italic>GLI2<\/jats:italic> and <jats:italic>PTCH1<\/jats:italic> were observed in tumour samples compared to healthy tissue. Protein expression of \u0394133p53\u03b1, \u0394160p53\u03b1 and \u0394Np73\u03b1 isoforms, NME1 and NME2, and N\u2032\u0394GLI1, GLI1FL, GLI2\u0394N isoforms was elevated in tumour tissue, whereas \u2206Np73\u03b2 was downregulated. The results in melanoma cell lines, in general, support these findings. In addition, we correlated expression profiles with clinical features and outcome. Higher \u0394133p53\u03b2 and p53\u03b1 mRNA and both <jats:italic>GLI1<\/jats:italic> mRNA and GLI3R protein expression had a negative impact on the overall survival. Shorter overall survival was also connected with lower p53\u03b2 and <jats:italic>NME1<\/jats:italic> gene expression levels. In conclusion, all examined genes may have implications in melanoma development and functional inactivity of <jats:italic>TP53<\/jats:italic>.<\/jats:p>","DOI":"10.1038\/s41598-019-48882-y","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T10:03:18Z","timestamp":1566986598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Expression profiles of p53\/p73, NME and GLI families in metastatic melanoma tissue and cell lines"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9757-6636","authenticated-orcid":false,"given":"Petar","family":"Ozreti\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolina","family":"Han\u017ei\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Proust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Sabol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Trnski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Radi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9927-3727","authenticated-orcid":false,"given":"Vesna","family":"Musani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9231-379X","authenticated-orcid":false,"given":"Yari","family":"Ciribilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Milas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvonimir","family":"Puljiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja Herak","family":"Bosnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Levanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3620-3099","authenticated-orcid":false,"given":"Neda","family":"Slade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"48882_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA. Cancer J. Clin. 63, 11\u201330 (2013).","journal-title":"CA. Cancer J. Clin."},{"key":"48882_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fonc.2015.00183","volume":"5","author":"G Palmieri","year":"2015","unstructured":"Palmieri, G. et al. Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. Front. Oncol. 5, 183 (2015).","journal-title":"Front. Oncol."},{"key":"48882_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1755-148X.2008.00495.x","volume":"21","author":"NF Box","year":"2008","unstructured":"Box, N. F. & Terzian, T. The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res. 21, 525\u2013533 (2008).","journal-title":"Pigment Cell Melanoma Res."},{"key":"48882_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-86","volume":"7","author":"G Palmieri","year":"2009","unstructured":"Palmieri, G. et al. Main roads to melanoma. J. Transl. Med. 7, 86 (2009).","journal-title":"J. Transl. Med."},{"key":"48882_CR5","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ccr.2013.03.013","volume":"23","author":"M Lu","year":"2013","unstructured":"Lu, M. et al. Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1\/CDK1-Phosphorylated Nuclear iASPP. Cancer Cell 23, 618\u2013633 (2013).","journal-title":"Cancer Cell"},{"key":"48882_CR6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1158\/1541-7786.371.2.7","volume":"2","author":"UM Moll","year":"2004","unstructured":"Moll, U. M. & Slade, N. p63 and p73: Roles in development and tumor formation. Mol. Cancer Res. 2, 371\u2013386 (2004).","journal-title":"Mol. Cancer Res."},{"key":"48882_CR7","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/sj.cdd.4401914","volume":"13","author":"F Murray-Zmijewski","year":"2006","unstructured":"Murray-Zmijewski, F., Lane, D. P. & Bourdon, J.-C. p53\/p63\/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 13, 962\u2013972 (2006).","journal-title":"Cell Death Differ."},{"key":"48882_CR8","doi-asserted-by":"publisher","first-page":"a026039","DOI":"10.1101\/cshperspect.a026039","volume":"6","author":"SM Joruiz","year":"2016","unstructured":"Joruiz, S. M. & Bourdon, J.-C. p53 Isoforms: Key Regulators of the Cell Fate Decision. Cold Spring Harb. Perspect. Med. 6, a026039 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"48882_CR9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1084\/jem.20020179","volume":"196","author":"AI Zaika","year":"2002","unstructured":"Zaika, A. I. et al. \u03b4Np73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 196, 765\u2013780 (2002).","journal-title":"J. Exp. Med."},{"key":"48882_CR10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2174\/138161211795222621","volume":"17","author":"N Slade","year":"2011","unstructured":"Slade, N. & Horvat, A. Targeting p73 -a Potential Approach in Cancer Treatment. Curr. Pharm. Des. 17, 591\u2013602 (2011).","journal-title":"Curr. Pharm. Des."},{"key":"48882_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1084\/jem.20121439","volume":"210","author":"RN Matin","year":"2013","unstructured":"Matin, R. N. et al. P63 Is an Alternative P53 Repressor in Melanoma That Confers Chemoresistance and a Poor Prognosis. J. Exp. Med. 210, 581\u2013603 (2013).","journal-title":"J. Exp. Med."},{"key":"48882_CR12","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1038\/onc.2012.322","volume":"32","author":"R Takahashi","year":"2013","unstructured":"Takahashi, R. et al. p53 isoform profiling in glioblastoma and injured brain. Oncogene 32, 3165\u20133174 (2013).","journal-title":"Oncogene"},{"key":"48882_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/jnci\/80.3.200","volume":"80","author":"PS Steeg","year":"1988","unstructured":"Steeg, P. S. et al. Evidence for a novel gene associated with low tumor metastatic potential. J. Natl. Cancer Inst. 80, 200\u2013204 (1988).","journal-title":"J. Natl. Cancer Inst."},{"key":"48882_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11010-009-0107-4","volume":"329","author":"MH Bosnar","year":"2009","unstructured":"Bosnar, M. H., Bago, R. & Cetkovi\u0107, H. Subcellular localization of Nm23\/NDPK A and B isoforms: a reflection of their biological function? Mol. Cell. Biochem. 329, 63\u201371 (2009).","journal-title":"Mol. Cell. Biochem."},{"key":"48882_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/00008390-199406000-00006","volume":"4","author":"MA Caligo","year":"1994","unstructured":"Caligo, M. A. et al. A low NM23.H1 gene expression identifying high malignancy human melanomas. Melanoma Res. 4, 179\u2013184 (1994).","journal-title":"Melanoma Res."},{"key":"48882_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/(SICI)1096-9896(200002)190:2<157::AID-PATH512>3.0.CO;2-J","volume":"190","author":"NC McDermott","year":"2000","unstructured":"McDermott, N. C. et al. Immunohistochemical expression of nm23 in primary invasive malignant melanoma is predictive of survival outcome. J. Pathol. 190, 157\u2013162 (2000).","journal-title":"J. Pathol."},{"key":"48882_CR17","first-page":"505","volume":"17","author":"B Bodey","year":"1997","unstructured":"Bodey, B., Bodey, B. J., Groeger, A. M., Siegel, S. E. & Haiser, H. E. Nm23\/nucleoside diphosphate (NDP) kinase expression in human malignant melanomas: significance and implications in tumor biology. Anticancer Res. 17, 505\u2013511 (1997).","journal-title":"Anticancer Res."},{"key":"48882_CR18","first-page":"1977","volume":"55","author":"H Baba","year":"1977","unstructured":"Baba, H. et al. Two isotypes of murine nm23\/nucleoside diphosphate kinase, nm23-M1 and nm23-M2, are involved in metastatic suppression of a murine melanoma line. Cancer Res. 55, 1977\u20131981 (1977).","journal-title":"Cancer Res."},{"key":"48882_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00210-011-0621-2","volume":"384","author":"M Novak","year":"2011","unstructured":"Novak, M., Jarrett, S. G., Mccorkle, J. R., Mellon, I. & Kaetzel, D. M. Multiple mechanisms underlie metastasis suppressor function of NM23-H1 in melanoma. Naunyn. Schmiedebergs. Arch. Pharmacol. 384, 433\u2013438 (2011).","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"48882_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1158\/0008-5472.CAN-11-1795","volume":"72","author":"SG Jarrett","year":"2012","unstructured":"Jarrett, S. G. et al. Metastasis suppressor NM23-H1 promotes repair of UV-induced DNA damage and suppresses UV-induced melanomagenesis. Cancer Res. 72, 133\u2013143 (2012).","journal-title":"Cancer Res."},{"key":"48882_CR21","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1111\/j.1745-7254.2008.00902.x","volume":"29","author":"R An","year":"2008","unstructured":"An, R. et al. Over-expression of nm23-H1 in HeLa cells provides cells with higher resistance to oxidative stress possibly due to raising intracellular p53 and GPX1. Acta Pharmacol. Sin. 29, 1451\u20131458 (2008).","journal-title":"Acta Pharmacol. Sin."},{"key":"48882_CR22","doi-asserted-by":"publisher","first-page":"35293","DOI":"10.1074\/jbc.M705181200","volume":"282","author":"H Jung","year":"2007","unstructured":"Jung, H., Seong, H.-A. & Ha, H. NM23-H1 tumor suppressor and its interacting partner STRAP activate p53 function. J. Biol. Chem. 282, 35293\u201335307 (2007).","journal-title":"J. Biol. Chem."},{"key":"48882_CR23","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/carcin\/bgr070","volume":"32","author":"R Polanski","year":"2011","unstructured":"Polanski, R. et al. MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility. Carcinogenesis 32, 1133\u20131142 (2011).","journal-title":"Carcinogenesis"},{"key":"48882_CR24","first-page":"73","volume":"23","author":"S Levanat","year":"2017","unstructured":"Levanat, S., Sabol, M., Musani, V., Ozreti\u0107, P. & Trnski, D. Hedgehog Signaling Pathway as Genetic and Epigenetic Target in Ovarian Tumors. Curr. Pharm. Des. 23, 73\u201394 (2017).","journal-title":"Curr. Pharm. Des."},{"key":"48882_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev-cellbio-092910-154048","volume":"27","author":"C Hui","year":"2011","unstructured":"Hui, C. & Angers, S. Gli Proteins in Development and Disease. Annu. Rev. Cell Dev. Biol. 27, 513\u2013537 (2011).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"48882_CR26","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1073\/pnas.0700776104","volume":"104","author":"B Stecca","year":"2007","unstructured":"Stecca, B. et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK\/AKT pathways. Proc. Natl. Acad. Sci. USA 104, 5895\u20135900 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"48882_CR27","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/jnci\/djq257","volume":"102","author":"V-I Alexaki","year":"2010","unstructured":"Alexaki, V.-I. et al. GLI2-mediated melanoma invasion and metastasis. J. Natl. Cancer Inst. 102, 1148\u20131159 (2010).","journal-title":"J. Natl. Cancer Inst."},{"key":"48882_CR28","doi-asserted-by":"publisher","first-page":"31523","DOI":"10.1074\/jbc.M109.059964","volume":"284","author":"S Dennler","year":"2009","unstructured":"Dennler, S., Andr\u00e9, J., Verrecchia, F. & Mauviel, A. Cloning of the human GLI2 Promoter: transcriptional activation by transforming growth factor-beta via SMAD3\/beta-catenin cooperation. J. Biol. Chem. 284, 31523\u201331 (2009).","journal-title":"J. Biol. Chem."},{"key":"48882_CR29","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.3390\/cancers7030857","volume":"7","author":"D Gu","year":"2015","unstructured":"Gu, D., Xie, J., Gu, D. & Xie, J. Non-Canonical Hh Signaling in Cancer\u2014Current Understanding and Future Directions. Cancers (Basel). 7, 1684\u20131698 (2015).","journal-title":"Cancers (Basel)."},{"key":"48882_CR30","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3892\/ijo_00000076","volume":"33","author":"Y Katoh","year":"1992","unstructured":"Katoh, Y. & Katoh, M. Integrative genomic analyses on GLI2: Mechanism of Hedgehog priming through basal GLI2 expression, and interaction map of stem cell signaling network with P53. Int. J. Oncol. 33, 881\u2013886 (1992).","journal-title":"Int. J. Oncol."},{"key":"48882_CR31","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1073\/pnas.0712216105","volume":"105","author":"Y Abe","year":"2008","unstructured":"Abe, Y. et al. Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2. Proc. Natl. Acad. Sci. USA 105, 4838\u20134843 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"48882_CR32","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/emboj.2009.16","volume":"28","author":"B Stecca","year":"2009","unstructured":"Stecca, B. & Ruiz i Altaba, A. A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. EMBO J. 28, 663\u2013676 (2009).","journal-title":"EMBO J."},{"key":"48882_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ccr.2009.05.013","volume":"16","author":"L Ho","year":"2009","unstructured":"Ho, L. et al. Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. Cancer Cell 16, 126\u2013136 (2009).","journal-title":"Cancer Cell"},{"key":"48882_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.yexcr.2011.12.010","volume":"318","author":"HN Kang","year":"2012","unstructured":"Kang, H. N., Oh, S. C., Kim, J. S. & Yoo, Y. A. Abrogation of Gli3 expression suppresses the growth of colon cancer cells via activation of p53. Exp. Cell Res. 318, 539\u2013549 (2012).","journal-title":"Exp. Cell Res."},{"key":"48882_CR35","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/onc.2009.482","volume":"29","author":"G Hofstetter","year":"2010","unstructured":"Hofstetter, G. et al. Alternative splicing of p53 and p73: the novel p53 splice variant p53\u03b4 is an independent prognostic marker in ovarian cancer. Oncogene 29, 1997\u20132004 (2010).","journal-title":"Oncogene"},{"key":"48882_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2811","volume":"13","author":"J-C Bourdon","year":"2011","unstructured":"Bourdon, J.-C. et al. p53 mutant breast cancer patients expressing p53\u03b3 have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res. 13, R7 (2011).","journal-title":"Breast Cancer Res."},{"key":"48882_CR37","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/carcin\/bgt411","volume":"35","author":"KA Avery-Kiejda","year":"2014","unstructured":"Avery-Kiejda, K. A., Morten, B., Wong-Brown, M. W., Mathe, A. & Scott, R. J. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. Carcinogenesis 35, 586\u2013596 (2014).","journal-title":"Carcinogenesis"},{"key":"48882_CR38","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3892\/ijo.2013.1818","volume":"42","author":"N Nutthasirikul","year":"2013","unstructured":"Nutthasirikul, N., Limpaiboon, T., Leelayuwat, C., Patrakitkomjorn, S. & Jearanaikoon, P. Ratio disruption of the \u0394133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma. Int. J. Oncol. 42, 1181\u20131188 (2013).","journal-title":"Int. J. Oncol."},{"key":"48882_CR39","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1158\/1078-0432.CCR-05-1970","volume":"12","author":"N Anensen","year":"2006","unstructured":"Anensen, N. et al. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin. Cancer Res. 12, 3985\u20133992 (2006).","journal-title":"Clin. Cancer Res."},{"key":"48882_CR40","doi-asserted-by":"crossref","unstructured":"Florijan, M. K. et al. The role of p53 isoforms\u2019 expression and p53 mutation status in renal cell cancer prognosis. Urologic Oncology: Seminars and Original Investigations 37(9), 578.e1\u2013578.e10 (2019).","DOI":"10.1016\/j.urolonc.2019.03.007"},{"key":"48882_CR41","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1158\/1078-0432.CCR-07-1422","volume":"14","author":"KA Avery-Kiejda","year":"2008","unstructured":"Avery-Kiejda, K. A. et al. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin. Cancer Res. 14, 1659\u20131668 (2008).","journal-title":"Clin. Cancer Res."},{"key":"48882_CR42","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/ijc.11552","volume":"108","author":"S Tuve","year":"2004","unstructured":"Tuve, S., Wagner, S. N., Schittek, B. & P\u00fctzer, B. M. Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression. Int. J. Cancer 108, 162\u2013166 (2004).","journal-title":"Int. J. Cancer"},{"key":"48882_CR43","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3390\/ph6111429","volume":"6","author":"KE O\u2019Reilly","year":"2013","unstructured":"O\u2019Reilly, K. E. et al. Hedgehog pathway blockade inhibits melanoma cell growth in vitro and in vivo. Pharmaceuticals (Basel). 6, 1429\u20131450 (2013).","journal-title":"Pharmaceuticals (Basel)."},{"key":"48882_CR44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/bjc.1996.323","volume":"74","author":"DJ Easty","year":"1996","unstructured":"Easty, D. J. et al. Expression of NM23 in human melanoma progression and metastasis. Br. J. Cancer 74, 109\u2013114 (1996).","journal-title":"Br. J. Cancer"},{"key":"48882_CR45","first-page":"6088","volume":"52","author":"VA Fl\u00f8renes","year":"1992","unstructured":"Fl\u00f8renes, V. A. et al. Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. Cancer Res. 52, 6088\u201391 (1992).","journal-title":"Cancer Res."},{"key":"48882_CR46","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1038\/onc.2013.399","volume":"33","author":"LS Fiore","year":"2014","unstructured":"Fiore, L. S. et al. c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer. Oncogene 33, 4508\u20134520 (2014).","journal-title":"Oncogene"},{"key":"48882_CR47","doi-asserted-by":"publisher","first-page":"5968","DOI":"10.1038\/sj.onc.1207780","volume":"23","author":"M Daniotti","year":"2004","unstructured":"Daniotti, M. et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23, 5968\u20135977 (2004).","journal-title":"Oncogene"},{"key":"48882_CR48","doi-asserted-by":"publisher","first-page":"e22096","DOI":"10.1371\/journal.pone.0022096","volume":"6","author":"R Houben","year":"2011","unstructured":"Houben, R. et al. High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PLoS One 6, e22096 (2011).","journal-title":"PLoS One"},{"key":"48882_CR49","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ijc.21366","volume":"118","author":"C Gwosdz","year":"2006","unstructured":"Gwosdz, C. et al. Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas. Int. J. Cancer 118, 577\u2013582 (2006).","journal-title":"Int. J. Cancer"},{"key":"48882_CR50","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/CMR.0000000000000151","volume":"25","author":"G Ganzetti","year":"2014","unstructured":"Ganzetti, G. et al. IL-17, IL-23, and p73 expression in cutaneous melanoma: A pilot study. Melanoma Res. 25, 232\u2013238 (2014).","journal-title":"Melanoma Res."},{"key":"48882_CR51","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ccr.2013.08.023","volume":"24","author":"M Steder","year":"2013","unstructured":"Steder, M. et al. DNp73 Exerts Function in Metastasis Initiation by Disconnecting the Inhibitory Role of EPLIN on IGF1R-AKT\/STAT3 Signaling. Cancer Cell 24, 512\u2013527 (2013).","journal-title":"Cancer Cell"},{"key":"48882_CR52","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1136\/gut.37.5.712","volume":"37","author":"JA Martinez","year":"1995","unstructured":"Martinez, J. A. et al. Overexpression of nm23-H1 and nm23-H2 genes in colorectal carcinomas and loss of nm23-H1 expression in advanced tumour stages. Gut 37, 712\u2013720 (1995).","journal-title":"Gut"},{"key":"48882_CR53","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.3390\/ijms19092562","volume":"19","author":"M Sabol","year":"2018","unstructured":"Sabol, M., Trnski, D., Musani, V., Ozreti\u0107, P. & Levanat, S. Role of GLI Transcription Factors in Pathogenesis and Their Potential as New Therapeutic Targets. Int. J. Mol. Sci. 19, 2562 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"48882_CR54","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/hmg\/ddi222","volume":"14","author":"E Roessler","year":"2005","unstructured":"Roessler, E. et al. A previously unidentified amino-terminal domain regulates transcriptional activity of wild-type and disease-associated human GLI2. Hum. Mol. Genet. 14, 2181\u20132188 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"48882_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.535","volume":"5","author":"E Pantazi","year":"2014","unstructured":"Pantazi, E. et al. GLI2 induces genomic instability in human keratinocytes by inhibiting apoptosis. Cell Death Dis. 5, e1028 (2014).","journal-title":"Cell Death Dis."},{"key":"48882_CR56","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251\u2013263 (2012).","journal-title":"Cell"},{"key":"48882_CR57","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/bjd.12504","volume":"169","author":"H Ekedahl","year":"2013","unstructured":"Ekedahl, H. et al. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br. J. Dermatol. 169, 1049\u20131055 (2013).","journal-title":"Br. J. Dermatol."},{"key":"48882_CR58","doi-asserted-by":"publisher","first-page":"e69064","DOI":"10.1371\/journal.pone.0069064","volume":"8","author":"A Jalili","year":"2013","unstructured":"Jalili, A. et al. NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo. PLoS One 8, e69064 (2013).","journal-title":"PLoS One"},{"key":"48882_CR59","doi-asserted-by":"publisher","first-page":"e14734d","DOI":"10.7554\/eLife.14734","volume":"5","author":"G Gadea","year":"2016","unstructured":"Gadea, G. et al. TP53 drives invasion through expression of its \u0394133p53\u03b2 variant. eLife 5, e14734d (2016).","journal-title":"eLife"},{"key":"48882_CR60","doi-asserted-by":"crossref","unstructured":"Zori\u0107, A., Horvat, A. & Slade, N. Differential Effects of Diverse p53 Isoforms on TAp73 Transcriptional Activity and Apoptosis. Carcinogenesis 34, 522\u2013529 (2012).","DOI":"10.1093\/carcin\/bgs370"},{"key":"48882_CR61","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1101\/gad.1339905","volume":"19","author":"J-C Bourdon","year":"2005","unstructured":"Bourdon, J.-C. et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19, 2122\u20132137 (2005).","journal-title":"Genes Dev."},{"key":"48882_CR62","first-page":"3971","volume":"20","author":"B D\u00f6me","year":"2000","unstructured":"D\u00f6me, B., Somlai, B. & T\u00edm\u00e1r, J. The loss of NM23 protein in malignant melanoma predicts lymphatic spread without affecting survival. Anticancer Res. 20, 3971\u20133974 (2000).","journal-title":"Anticancer Res."},{"key":"48882_CR63","first-page":"2293","volume":"37","author":"D Ma","year":"1996","unstructured":"Ma, D., Luyten, G. P., Luider, T. M., Jager, M. J. & Niederkorn, J. Y. Association between NM23-H1 gene expression and metastasis of human uveal melanoma in an animal model. Invest. Ophthalmol. Vis. Sci. 37, 2293\u20132301 (1996).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"48882_CR64","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/sj.bjc.6601117","volume":"89","author":"TG Clark","year":"2003","unstructured":"Clark, T. G., Bradburn, M. J., Love, S. B. & Altman, D. G. Survival Analysis Part IV: Further concepts and methods in survival analysis. Br. J. Cancer 89, 781\u2013786 (2003).","journal-title":"Br. J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48882-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48882-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48882-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:56:37Z","timestamp":1671281797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48882-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["48882"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-48882-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"4 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12470"}}